Pharmaceutical Strategy Analysis l Report Store l Pharma Intelligence

Multiple Sclerosis KOL Insight Interview

October 28, 2014

Retinal Disorders (AMD and DME) Pulse

We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).

October 27, 2014

Find out more

Inpatient Infections Pulse

$599.00

We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.

October 8, 2014

Find out more

GLP-1 Pulse Survey

$599.00

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

August 25, 2014

Find out more

SGLT-2 Pulse Survey

$599.00

We surveyed primary care physicians (n=10) and endocrinologists (n=10) to see how SGLT-2 inhibitors and the combo pills will be used and what the potential impact of usage with GLP-1 agonists may have.

August 25, 2014

Find out more

Post-AAIC KOL Interview

$599.00

Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

August 6, 2014

Find out more

Dyslipidemia KOL Insight Interview #2

$599.00

Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.

July 28, 2014

Find out more

Dyslipidemia KOL Insight Interview #1

$599.00

Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data

July 25, 2014

Find out more

Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

$599.00

Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.

May 13, 2014

Find out more

Breast Cancer KOL Insight Interview

$599.00

Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent
change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.

May 8, 2014

Find out more

Ovarian Cancer Pulse Survey

$599.00

Diagnostics/diagnostic techniques discussed:

etarfolatide/folic acid, BRCA mutation testing

May 7, 2014

Find out more

Post-EASL KOL Insight Interview

$599.00

The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
soon-to-be approved, direct-acting antivirals for Hepatitis C.

May 6, 2014

Find out more